An association of boswellia, betaine and myo-inositol (Eumastós®) in the treatment of mammographic breast density: A randomized, double-blind study

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 22, 2015, Pages 4419-4426

  Pasta, V ^a,b   Gullo, G ^c   Giuliani, A ^d   Harrath, A H ^e   Alwasel, S H ^e   Tartaglia, F ^a,b   Cucina, A ^a,b   Bizzarri, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Betaine; Boswellic acid; Breast density; Mammographic density; Myo inositol

Indexed keywords

BETAINE; INOSITOL;

ADULT; BOSWELLIA; BREAST; BREAST NEOPLASMS; COMBINATION DRUG THERAPY; CONGENITAL MALFORMATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HUMAN; MAMMARY GLAND; MAMMOGRAPHY; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADULT; BETAINE; BOSWELLIA; BREAST; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INOSITOL; MAMMARY GLANDS, HUMAN; MAMMOGRAPHY; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957953321     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. URSIN G, QURESHI SA. Mammographic density - a useful biomarker for breast cancer risk in epidemiologic studies. Norsk Epidemiologi 2009; 19: 59-68.
2. BOYD NF, GUO H, MARTIN LJ, SUN L, STONE J, FISHELL E, JONG RA, HISLOP G, CHIARELLI A, MINKIN S, YAFFE MJ. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227-236.
3. BOYD NF, MARTIN LJ, YAFFE MJ, MINKIN S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011; 13: 223.
4. BOYD NF, MARTIN LJ, BRONSKILL M, YAFFE MJ, DURIC N, MINKIN S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst 2010; 102: 1224-1237.
5. PANG JMB, BYRNE DJ, TAKANO EA, JENE N, PETELIN L, MCKINLEY J, POLINESS C, SAUNDERS C, TAYLOR D, MITCHELL G, FOX SB. Breast tissue composition and immunophenotype and its relationship with mammographic density in women at high risk of breast cancer. PLoS One 2015; 10: e0128861.
6. TICE JA, O'MEARA ES, WEAVER DL, VACHON C, BALLARDBARBASH R, KERLIKOWSKE K. Benign breast disease, mammographic breast density, and the risk of breast cancer. J Natl Cancer Inst 2013; 105: 1043-1049.
7. OZA AM, BOYD NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993; 15: 196-208.
8. FISHER ER, PALEKAR A, KIM WS, REDMOND C. The histopathology of mammographic patterns. Am J Clin Pathol 1978; 69: 421-426.
9. ARTHUR JE, ELLIS IO, FLOWERS C, ROEBUCK E, ELSTON CW, BLAMEY RW. The relationship of "high risk" mammographic patterns to histological risk factors for development of cancer in the human breast. Br J Radiol 1990; 63: 845-849.
10. HAWES D, DOWNEY S, PEARCE CL, BARTOW S, WAN P, PIKE MC, WU AH. Dense breast stromal tissue shows greatly increased concentration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res 2006; 8: R24.
11. GUO YP, MARTIN LJ, HANNA W, BANERJEE D, MILLER N, FISHELL E, KHOKHA R, BOYD NF. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001; 10: 243-248.
12. ALOWAMI S, TROUP S, AL-HADDAD S, KIRKPATRICK I, WATSON PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003; 5: R129-135.
13. HAGIOS C, LOCHTER A, BISSELL M. Tissue architecture: the ultimate regulator of epithelial function? Philos Trans R Soc Lond B Biol Sci 1998; 353: 857-870.
14. ZANGANI D, DARCY KM, MASSO-WELCH PA, BELLAMY ES, DESOLE MS, IP MM. Multiple differentiation pathways of rat mammary stromal cells in vitro: acquisition of a fibroblast, adipocyte or endothelial phenotype is dependent on hormonal and extracellular matrix stimulation. Differentiation 1999; 64: 91-101.
15. BARCELLOS-HOFF MH, MEDINA D. New highlights on stroma-epithelial interactions in breast cancer. Breast Cancer Res 2005; 7: 33-36.
16. BYRNE C, SCHAIRER C, WOLFE J, PAREKH N, SALANE M, BRINTON LA, HOOVER R, HAILE R. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995; 87: 1622-1629.
17. GROVE JS, GOODMAN MJ, GILBERT FI, CLYDE D. Factors associated with breast structures in breast cancer patients. Cancer 1979; 43: 1895-1899.
18. WOLFE JN. Breast parenchymal patterns and their changes with age. Radiology 1976; 121(3 pt 1): 545-552.
19. MILANESE TR, HARTMANN LC, SELLERS TA, FROST MH, VIERKANT RA, MALONEY SD, PANKRATZ VS, DEGNIM AC, VACHON CM, REYNOLDS CA, THOMPSON RA, MELTON LJ 3RD, GOODE EL, VISSCHER DW. Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 2006; 98: 1600-1607.
20. LI T, SUN L, MILLER N, NICKLEE T, WOO J, HULSE-SMITH L, TSAO MS, KHOKHA R, MARTIN L, BOYD N. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 343-349.
21. RUDOLPH A, FASCHING PA, BEHRENS S, EILBER U, BOLLA MK, WANG Q, THOMPSON D, CZENE K, BRAND JS, LI J, SCOTT C, PANKRATZ VS, BRANDT K, HALLBERG E, OLSON JE, LEE A, BECKMANN MW, EKICI AB, HAEBERLE L, MASKARINEC G, LE MARCHAND L, SCHUMACHER F, MILNE RL, KNIGHT JA, APICELLA C, SOUTHEY MC, KAPUSCINSKI MK, HOPPER JL, ANDRULIS IL, GILES GG, HAIMAN CA, KHAW KT, LUBEN R, HALL P, PHAROAH PD, COUCH FJ, EASTON DF, DOS-SANTOS-SILVA I, VACHON C, CHANGCLAUDE J. A comprehensive evaluation of interact ion between genet ic var iants and use of menopausal hormone therapy on mammographic density. Breast Cancer Res 2015; 17: 110.
22. MARTIN LJ, BOYD NF. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008; 10: 201.
23. NAM SY, LOBIE PE. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev 2000; 1: 73-86.
24. CUZICK J, WARWICK J, PINNEY E, DUFFY SW, CAWTHORN S, HOWELL A, FORBES JF, WARREN RM. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011; 103: 744-752.
25. CUZICK J, WARWICK J, PINNEY E, WARREN RM, DUFFY SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004; 96: 621-628.
26. SPICER DV, URSIN G, PARISKY YR, PEARCE JG, SHOUPE D, PIKE A, PIKE MC. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994; 86: 431-436.
27. LIAO J, SERIL DN, YANG AL, LU GG, YANG GY. Inhibition of chronic ulcerative colitis associated adenocarcinoma development in mice by inositol compounds. Carcinogenesis 2007; 28: 446-454.
28. GIORDANO D, CORRADO F, SANTAMARIA A, QUATTRONE S, PINTAUDI B, DI BENEDETTO A, D'ANNA R. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-cont rol led study. Menopause 2011; 18: 102-104.
29. DONÀ G, SABBADIN C, FIORE C, BRAGADIN M, GIORGINO FL, RAGAZZI E, CLARI G, BORDIN L, ARMANINI D. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol 2012; 166: 703-710.
30. SHAMSUDDIN AM. Anti-cancer function of phytic acid. Int J Food Sci Technol 2002; 37: 769-782.
31. DETOPOULOU P, PANAGIOTAKOS DB, ANTONOPOULOU S, PITSAVOS C, STEFANADIS C. Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study. Am J Clin Nutr 2008; 87: 424-430.
32. GO EK, JUNG KJ, KIM JY, YU BP, CHUNG HY. Betaine suppresses proinflammatory signaling during aging: the involvement of nuclear factor-kappaB via nuclear factor-inducing kinase/IkappaB kinase and mitogen-activated protein kinases. J Gerontol 2005; 60: 1252-1264.
33. CHO E, HOLMES MD, HANKINSON SE, WILLETT WC. Choline and betaine intake and risk of breast cancer among post-menopausal women. Br J Cancer 2010; 102: 489-494.
34. AMMON HP. Boswellic acids in chronic inflammatory diseases. Planta Med 2006; 72: 1100-1116.
35. BOYD NF, GUO H, MARTIN LJ, SUN L, STONE J, FISHELL E, JONG RA, HISLOP G, CHIARELLI A, MINKIN S, YAFFE MJ. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227-236.
36. GREENDALE GA, REBOUSSIN BA, SLONE S, WASILAUSKUS C, PIKE MC, URSIN G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003; 95: 30-37.
37. STUEDAL A, MA H, BJORNDAL H, URSIN G. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. Climacteric 2009; 12: 248-258.
38. CUZICK J, POWLES T, VERONESI U, FORBES J, EDWARDS R, ASHLEY S, BOYLE P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
39. GRAHAM S, HELLMANN R, MARSHALL J, FREUDENHEIM J, VENA J, SWANSON M, ZIELEZNY M, NEMOTO T, STUBBE N, RAIMONDO T. Nutritional epidemiology of postmenopausal breast cancer in western New York. Am J Epidemiol 1991; 134: 552-566.
40. LAJOUS M, LAZCANO-PONCE E, HERNANDEZ-AVILA M, WILLETT W, ROMIEU I. Folate, Vitamin B(6), and Vitamin B(12) intake and the risk of breast cancer among Mexican women. Cancer Epidemiol Biomarkers Prev 2006; 15: 443-448.
41. DE BATLLE J, FERRARI P, CHAJES V, PARK JY, SLIMANI N, MCKENZIE F, OVERVAD K, ROSWALL N, TJØNNELAND A, BOUTRON-RUAULT MC, CLAVEL-CHAPELON F, FAGHERAZZI G, KATZKE V, KAAKS R, BERGMANN MM, TRICHOPOULOU A, LAGIOU P, TRICHOPOULOS D, PALLI D, SIERI S, PANICO S, TUMINO R, VINEIS P, BUENO-DE-MESQUITA HB, PEETERS PH, HJARTÅKER A, ENGESET D, WEIDERPASS E, SÁNCHEZ S, TRAVIER N, SÁNCHEZ MJ, AMIANO P, CHIRLAQUE MD, BARRICARTE GURREA A, KHAW KT, KEY TJ, BRADBURY KE, ERICSON U, SONESTEDT E, VAN GUELPEN B, SCHNEEDE J, RIBOLI E, ROMIEU I. Dietary folate intake and breast cancer risk: European prospective investigation into cancer and nutrition. J Natl Cancer Inst 2014; 107: 367.
42. VACHON CM, KUSHI LH, CERHAN JR, KUNI CC, SELLERS TA. Association of diet and mammographic breast density in the Minnesota breast cancer family cohort. Cancer Epidemiol Biomarkers Prev 2000; 9: 151-160.
43. VENUGOPAL D, ZAHID M, MAILANDER P, MEZA JL, ROGAN EG, CAVALIERI EL, CHAKRAVARTI D. Reduction of estrogen-induced transformation of mouse mammary epithelial cells by N-acetylcysteine. J Steroid Biochem Mol Biol 2008; 109: 22-30.
44. ABDEL-TAWAB M, WERZ O, SCHUBERT-ZSILAVECZ M. BOSWELLIA serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet 2011; 50: 349-369.
45. AMMON HP. Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Phytomedicine 2010; 17: 862-867.
46. AMMON HP. Boswellic acids in chronic inflammatory diseases. Planta Med 2006; 72: 1100-1116.
47. POECKEL D, WERZ O. Boswellic acids: biological actions and molecular targets. Curr Med Chem 2006; 13: 3359-3369.
48. YADAV VR, PRASAD S, SUNG B, GELOVANI JG, GUHA S, KRISHNAN S, AGGARWAL BB. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive, and angiogenic biomarkers. Int J Cancer 2012; 130: 2176-2184.
49. TOLGA EICHHORN T, GRETEN HJ, THOMAS EFFERTH T. Molecular determinants of the response of tumor cells to boswellic acids. Pharmaceuticals (Basel) 2011; 4: 1171-1182.
50. LIU JJ, NILSSON A, OREDSSON S, BADMAEV V, DUAN RD. Keto- and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via acaspase-8 dependent pathway. Int J Mol Med 2002; 10: 501-505.
51. LIU JJ, NILSSON A, OREDSSON S, BADMAEV V, ZHAO WZ, DUAN RD. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 2002; 23: 2087-2093.
52. LU M, XIA L, HUA H, JING Y. Acetyl-keto-betaboswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer Res 2008; 68: 1180-1186.
53. SUHAIL MM, WU W, CAO A, MONDALEK FG, FUNG KM, SHIH PT, FANG YT, WOOLLEY C, YOUNG G, LIN HK. Boswellia sacra essential oil induces tumor cellspecific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells. BMC Complement Altern Med 2011; 11: 129.
54. KAMP DW, ISRABIAN VA, YELDANDI AV, PANOS RJ, GRACEFFA P, WEITZMAN SA. Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos. Toxicol Pathol 1995; 23: 689-695.
55. SUDHEER KUMAR M, SRIDHAR REDDY B, KIRAN BABU S, BHILEGAONKAR PM, SHIRWAIKAR A, UNNIKRISHNAN MK. Antiinflammatory and antiulcer activities of phytic acid in rats. Indian J Exp Biol 2004; 42: 179-185.
56. DI SABATINO A, JACKSON CL, PICKARD KM, BUCKLEY M, ROVEDATTI L, LEAKEY NA, PICARIELLO L, CAZZOLA P, MONTELEONE G, TONELLI F, CORAZZA GR, MACDONALD TT, PENDER SL. Transforming growth factor β signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009; 58: 777-789.
57. Umar S, Umar K, Sarwar AH, Khan A, Ahmad N, Ahmad S, Katiyar CK, Husain SA, Khan HA. Boswellia serrata extract attenuates inflammatory mediators andoxidative stress in collagen induced arthritis. Phytomedicine 2014; 21: 847-856.
58. KAPRAL M, WAWSZCZYK J, JURZAK M, HOLLEK A, WEGLARZ L. The effect of inositol hexaphosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1-stimulated colon cancer cells. Int J Colorectal Dis 2012; 27: 1419-1428.
59. WEGLARZ L, WAWSZCZYK J, ORCHEL A, JAWORSKA-KIK M, DZIERZEWICZ ZL. Phytic acid modulates in vitro IL-8 and IL-6 release from colonic epithelial cells stimulated with LPS and IL-1beta. Dig Dis Sci 2007; 52: 93-102.
60. WAWSZCZYK J, KAPRAL M, HOLLEK A, WEGLARZ L. The effect of phytic acid on the expression of NF-kappaB, IL-6 and IL-8 in IL-1beta-stimulated human colonic epithelial cells. Acta Pol Pharm 2012; 69: 1313-1319.
61. GOBBI H, DUPONT WD, SIMPSON JF, PLUMMER WD JR, SCHUYLER PA, OLSON SJ, ARTEAGA CL, PAGE DL. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999; 91: 2096-2101.
62. ONOMI S, OKAZAKI Y, KATAYAMA T. Effect of dietary level of phytic acid on hepatic and serum lipid status in rats fed a high-sucrose diet. Biosci Biotechnol Biochem 2004; 68: 1379-1381.
63. GENAZZANI AD, LANZONI C, RICCHIERI F, JASONNI VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008; 24: 139-144.
64. COSTANTINO D, MINOZZI G, MINOZZI E, GUARALDI C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a doubleblind trial. Eur Rev Med Pharmacol Sci 2009; 13: 105-110.
65. HUANG LC, FONTELES MC, HOUSTON DB, ZHANG C, LARNER J. Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology 1993; 132: 652-657.
66. ORIHUELA PA, PARADA-BUSTAMANTE A, ZUÑIGA LM, CROXATTO HB. Inositol triphosphate participates in an oestradiol nongenomic signalling pathway involved in accelerated oviductal transport in cycling rats. J Endocrinol 2006; 188: 579-588.
67. ZHANG CX, PAN MX, LI B, WANG L, MO XF, CHEN YM, LIN FY, HO SC. Choline and betaine intake is inversely associated with breast cancer risk: a twostage case-control study in China. Cancer Sci 2013; 104: 250-258.
68. XU X, GAMMON MD, ZEISEL SH, BRADSHAW PT, WETMUR JG, TEITELBAUM SL, NEUGUT AI, SANTELLA RM, CHEN J. High intakes of choline and betaine reduce breast cancer mortality in a populationbased study. FASEB J 2009; 23: 4022-4028.